TY - JOUR T1 - The COVIDome Explorer Researcher Portal JF - medRxiv DO - 10.1101/2021.03.04.21252945 SP - 2021.03.04.21252945 AU - Kelly D. Sullivan AU - Matthew D. Galbraith AU - Kohl T. Kinning AU - Kyle Bartsch AU - Nik Levinsky AU - Paula Araya AU - Keith P. Smith AU - Ross E. Granrath AU - Jessica R. Shaw AU - Ryan Baxter AU - Kimberly R. Jordan AU - Seth Russell AU - Monika Dzieciatkowska AU - Julie A. Reisz AU - Fabia Gamboni AU - Francesca Cendali AU - Tusharkanti Ghosh AU - Andrew A. Monte AU - Tellen D. Bennett AU - Michael G. Miller AU - Elena W.Y. Hsieh AU - Angelo D’Alessandro AU - Kirk C. Hansen AU - Joaquin M. Espinosa Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.04.21252945.abstract N2 - COVID-19 pathology involves dysregulation of diverse molecular, cellular, and physiological processes. In order to expedite integrated and collaborative COVID-19 research, we completed multi-omics analysis of hospitalized COVID-19 patients including matched analysis of the whole blood transcriptome, plasma proteomics with two complementary platforms, cytokine profiling, plasma and red blood cell metabolomics, deep immune cell phenotyping by mass cytometry, and clinical data annotation. We refer to this multidimensional dataset as the COVIDome. We then created the COVIDome Explorer, an online researcher portal where the data can be analyzed and visualized in real time. We illustrate here the use of the COVIDome dataset through a multi-omics analysis of biosignatures associated with C-reactive protein (CRP), an established marker of poor prognosis in COVID-19, revealing associations between CRP levels and damage-associated molecular patterns, depletion of protective serpins, and mitochondrial metabolism dysregulation. We expect that the COVIDome Explorer will rapidly accelerate data sharing, hypothesis testing, and discoveries worldwide.Competing Interest StatementKDS and JME are co-inventors on two patents related to JAK inhibition in COVID-19; JME serves in the COVID Development Advisory Board for Elly Lilly and has provided consulting services to Gilead Sciences Inc.Funding StatementThis work was supported by NIH grants R01AI150305, 3R01AI150305-01S1, R01AI145988, UL1TR002535, 3UL1TR002535-03S2, R01HL146442, R01HL149714, R01HL148151, R21HL150032, P30CA046934, R35GM124939 and RM1GM131968, as well as grants from the Boettcher Foundation and Fast Grants. Additional support was received from Chancellors Discovery Innovation Fund at the CU Anschutz Medical Campus, the Global Down Syndrome Foundation, the Anna and John J. Sie Foundation, and Lyda Hill Philanthropies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research participants were recruited and consented for participation in the COVID Biobank of the University of Colorado Anschutz Medical Campus [Colorado Multiple Institutional Review Board (COMIRB) Protocol # 20-0685]. Data was generated from deidentified biospecimens and linked to demographics and clinical metadata procured through the Health Data Compass of the University of Colorado under COMIRB Protocol # 20-1700.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated for this manuscript is made available through the online researcher gateway of the COVIDome Project, known as the COVIDome Explorer, which can be accessed at covidome.org. The RNAseq data have been deposited in NCBI Gene Expression Omnibus, with series accession number GSE167000. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (Perez-Riverol et al., 2019) with the dataset identifier PXD022817. The mass cytometry data has been deposited in Flow Repository under the link: https://flowrepository.org/id/RvFrSYioKeUdYHXdkTD9TQPAXt4PqdkB5eie82h11JgAGSCQIneLKpcKd81Nzgwq. The SOMAscan Proteomics, MSD Cytokine Profiles, and Sample Metadata files have been deposited in Mendeley under entry doi:10.17632/2mc6rrc5j3.1. The metabolomics data have been deposited in the Metabolomics Workbench with a Study ID to be made available upon acceptance. All code required to run the COVIDome Explorer applications can be found at https://github.com/cusom/CUSOM.COVIDome.Shiny-Apps and https://github.com/cusom/CUSOM.ShinyHelpers. https://flowrepository.org/id/RvFrSYioKeUdYHXdkTD9TQPAXt4PqdkB5eie82h11JgAGSCQIneLKpcKd81Nzgwq https://github.com/cusom/CUSOM.COVIDome.Shiny-Apps https://github.com/cusom/CUSOM.ShinyHelpers https://data.mendeley.com/datasets/2mc6rrc5j3/1 http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD022817 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167000 ER -